{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:30:08Z","timestamp":1793932208546,"version":"4.8.0"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["BK20221522"],"award-info":[{"award-number":["BK20221522"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bmc.2025.118180","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T19:24:11Z","timestamp":1743967451000},"page":"118180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Brief analysis of Nav1.7 inhibitors: Mechanism of action and new research trends"],"prefix":"10.1016","volume":"128","author":[{"given":"Zhoujun","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baichen","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijia","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5109-0304","authenticated-orcid":false,"given":"Haopeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118180_b0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12264-018-0203-0","article-title":"Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7: Differential activities of Nav1.7-targeting monoclonal antibodies","volume":"34","author":"Bang","year":"2018","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.bmc.2025.118180_b0010","doi-asserted-by":"crossref","first-page":"e869","DOI":"10.1097\/j.pain.0000000000002490","article-title":"Examination of the contribution of Nav1.7 to axonal propagation in nociceptors","volume":"163","author":"Goodwin","year":"2022","journal-title":"Pain"},{"key":"10.1016\/j.bmc.2025.118180_b0015","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1016\/j.neuron.2023.05.024","article-title":"Nav1.7 is essential for nociceptor action potentials in the mouse in a manner independent of endogenous opioids","volume":"111","author":"Deng","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.bmc.2025.118180_b0020","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1517\/14728222.2016.1162295","article-title":"Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief","volume":"20","author":"Emery","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.bmc.2025.118180_b0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/bmb\/ldaa003","article-title":"Understanding the genetic basis of congenital insensitivity to pain","volume":"133","author":"Drissi","year":"2020","journal-title":"Br Med Bull"},{"key":"10.1016\/j.bmc.2025.118180_b0030","doi-asserted-by":"crossref","unstructured":"Bennett DL, Clark AJ, Huang J, et al. The Role of Voltage-Gated Sodium Channels in Pain Signaling. 2019;99(2): 1079-1151.","DOI":"10.1152\/physrev.00052.2017"},{"key":"10.1016\/j.bmc.2025.118180_b0035","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2147\/JPR.S388896","article-title":"A Review of the Therapeutic Targeting of SCN9A and Nav1.7 for Pain Relief in Current Human Clinical Trials","volume":"16","author":"Dormer","year":"2023","journal-title":"J Pain Res"},{"key":"10.1016\/j.bmc.2025.118180_b0040","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4155\/ppa.14.39","article-title":"Inhibitors of voltage-gated Sodium Channel Nav1.7: Patent Applications Since 2010","volume":"3","author":"Sun","year":"2014","journal-title":"Pharm Pat Anal"},{"key":"10.1016\/j.bmc.2025.118180_b0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cbpa.2021.04.009","article-title":"Recent progress on the prospective application of machine learning to structure-based virtual screening","volume":"65","author":"Ghislat","year":"2021","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.bmc.2025.118180_b0050","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/acs.jmedchem.1c00028","article-title":"Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery","volume":"64","author":"Obeng","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118180_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107605","article-title":"Recent advances in small molecule Nav 1.7 inhibitors for cancer pain management","volume":"150","author":"Yu","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118180_b0060","article-title":"Voltage-Gated Sodium Channel Dysfunctions in Neurological Disorders","volume":"13","author":"Barbieri","year":"2023","journal-title":"Life (Basel, Switzerland)"},{"key":"10.1016\/j.bmc.2025.118180_b0065","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.aaw2999","article-title":"Molecular basis for pore blockade of human Na+ channel Nav1.2 by the \u03bc-conotoxin KIIIA","volume":"363","author":"Pan","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.bmc.2025.118180_b0070","first-page":"314","article-title":"Physiological and Pathophysiological Insights of Nav1.4 and Nav1.5 Comparison","volume":"6","author":"Loussouarn","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2025.118180_b0075","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10571-022-01211-w","article-title":"Structure and Function of Sodium Channel Nav1.3 in Ne urological Disorders","volume":"43","author":"Liao","year":"2023","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.bmc.2025.118180_b0080","article-title":"SCN5A channelopathy: arrhythmia, cardiomyopathy, epilepsy and beyond","volume":"378","author":"Remme","year":"2023","journal-title":"Philos Trans R Soc London Ser B Biol Sci"},{"key":"10.1016\/j.bmc.2025.118180_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071595","article-title":"Distinctive Properties and Powerful Neuromodulation of Na(v)1.6 Sodium Channels Regulates Neuronal Excitability","volume":"10","author":"Zybura","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bmc.2025.118180_b0090","doi-asserted-by":"crossref","DOI":"10.1085\/jgp.202012722","article-title":"Structural basis of cytoplasmic NaV1.5 and NaV1.4 regulation","volume":"153","author":"Nathan","year":"2021","journal-title":"J Gen Physiol"},{"key":"10.1016\/j.bmc.2025.118180_b0095","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cell.2019.11.041","article-title":"Structure of the Cardiac Sodium Channel","volume":"180","author":"Jiang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2025.118180_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135844","article-title":"Pain behavior in SCN9A (Nav1.7) and SCN10A (Nav1.8) mutant rodent models","volume":"753","author":"Xue","year":"2021","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bmc.2025.118180_b0105","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00424-020-02419-9","article-title":"Painful and painless mutations of SCN9A and SCN11A voltage-gated sodium channels","volume":"472","author":"Baker","year":"2020","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.bmc.2025.118180_b0110","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nature05413","article-title":"An SCN9A channelopathy causes congenital inability to experience pain","volume":"444","author":"Cox","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118180_b0115","article-title":"Comparison of Gating Properties and Use-Dependent Block of Nav1.5 and Nav1.7 Channels by Anti-Arrhythmics Mexiletine and Lidocaine","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2025.118180_b0120","doi-asserted-by":"crossref","first-page":"602","DOI":"10.5312\/wjo.v15.i6.602","article-title":"Carbamazepine in osteoarthritis treatment: A novel approach targeting Nav1.7 channels","volume":"15","author":"Vaid","year":"2024","journal-title":"World J Orthop"},{"key":"10.1016\/j.bmc.2025.118180_b0125","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jpain.2006.10.001","article-title":"Sodium channel blockade may contribute to the analgesic efficacy of antidepressants","volume":"8","author":"Dick","year":"2007","journal-title":"J Pain"},{"key":"10.1016\/j.bmc.2025.118180_b0130","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1111\/bph.12788","article-title":"Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels","volume":"171","author":"Cregg","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2025.118180_b0135","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0022-3565(24)37206-4","article-title":"Inhibition of neuronal Na+ channels by antidepressant drugs","volume":"284","author":"Pancrazio","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmc.2025.118180_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/nu16111683","article-title":"Atractylodes macrocephala Koidz Alleviates Symptoms in Zymosan-Induced Irritable Bowel Syndrome Mouse Model through TRPV1, NaV1.5, and NaV1.7 Channel Modulation","volume":"16","author":"Choi","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.bmc.2025.118180_b0145","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1021\/acs.jmedchem.7b00598","article-title":"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na(V)1.7","volume":"60","author":"Swain","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118180_b0150","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/cn500171p","article-title":"No gain, no pain: NaV1.7 as an analgesic target","volume":"5","author":"King","year":"2014","journal-title":"ACS Chem Nerosci"},{"key":"10.1016\/j.bmc.2025.118180_b0155","doi-asserted-by":"crossref","first-page":"6866","DOI":"10.1021\/jm300623u","article-title":"3-Oxoisoindoline-1-carboxamides: potent, state-dependent blockers of voltage-gated sodium channel Na(V)1.7 with efficacy in rat pain models","volume":"55","author":"Macsari","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118180_b0160","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1021\/acs.jmedchem.6b00063","article-title":"Substituted Indazoles as Nav1.7 Blockers for the Treatment of Pain","volume":"59","author":"Frost","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118180_b0165","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1021\/jm200018k","article-title":"Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain","volume":"54","author":"Bregman","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118180_b0170","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1021\/acs.jmedchem.8b01906","article-title":"Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium Channel Isoform NaV1.7","volume":"62","author":"Mulcahy","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118180_b0175","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1016\/j.bmcl.2017.09.056","article-title":"Highly potent and selective NaV1.7 inhibitors for use as intravenous agents and chemical probes","volume":"27","author":"Storer","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118180_b0180","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1021\/acs.jmedchem.9b00141","article-title":"Structure- and Ligand-Based Discovery of Chromane Arylsulfonamide Nav1.7 Inhibitors for the Treatment of Chronic Pain","volume":"62","author":"McKerrall","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118180_b0185","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1021\/acsmedchemlett.6b00243","article-title":"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement","volume":"7","author":"Marx","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118180_b0190","doi-asserted-by":"crossref","first-page":"5990","DOI":"10.1021\/acs.jmedchem.6b01850","article-title":"Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity","volume":"60","author":"Graceffa","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118180_b0195","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1016\/j.bmcl.2014.08.017","article-title":"The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Nav1.7","volume":"24","author":"Sun","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118180_b0200","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1021\/acsmedchemlett.5b00447","article-title":"Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models","volume":"7","author":"Focken","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118180_b0205","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1021\/acs.jmedchem.8b01621","article-title":"Identification of Selective Acyl Sulfonamide-Cycloalkylether Inhibitors of the Voltage-Gated Sodium Channel (NaV) 1.7 with Potent Analgesic Activity","volume":"62","author":"Sun","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118180_b0210","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.bmcl.2017.03.085","article-title":"Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice","volume":"27","author":"Roecker","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118180_b0215","doi-asserted-by":"crossref","first-page":"10204","DOI":"10.1021\/acs.jmedchem.0c00259","article-title":"Discovery of DS-1971a, a Potent, Selective NaV1.7 Inhibitor","volume":"63","author":"Shinozuka","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118180_b0220","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1021\/acschemneuro.3c00353","article-title":"Nav1.7 Modulator Bearing a 3-Hydroxyindole Backbone Holds the Potential to Reverse Neuropathic Pain","volume":"15","author":"Wang","year":"2024","journal-title":"ACS Chem Nerosci"},{"key":"10.1016\/j.bmc.2025.118180_b0225","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00424-021-02656-6","article-title":"Functional subgroups of rat and human sensory neurons: a systematic review of electrophysiological properties","volume":"474","author":"K\u00f6rner","year":"2022","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.bmc.2025.118180_b0230","doi-asserted-by":"crossref","unstructured":"Eagles DA, Chow CY, King GF. Fifteen years of NaV1.7 channels as an analgesic target: Why has excellent in vitro pharmacology not translated into in vivo analgesic efficacy? 2022;179(14): 3592-3611.","DOI":"10.1111\/bph.15327"},{"key":"10.1016\/j.bmc.2025.118180_b0235","unstructured":"47. Yang J, Xie Y-F, Smith R, et al. Discordance between preclinical and clinical testing of NaV1.7-selective inhibitors for pain. 9900: 10.1097\/j.pain.0000000000003425."},{"key":"10.1016\/j.bmc.2025.118180_b0240","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1021\/acs.jmedchem.1c00049","article-title":"Discovery of Acyl-sulfonamide Na(v)1.7 Inhibitors GDC-0276 and GDC-0310","volume":"64","author":"Safina","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118180_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.104346","article-title":"In silico development of potential therapeutic for the pain treatment by inhibiting voltage-gated sodium channel 1.7","volume":"132","author":"Golubovic","year":"2021","journal-title":"Comput Biol Med"},{"key":"10.1016\/j.bmc.2025.118180_b0250","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1152\/jn.00457.2022","article-title":"Nav1.7 P610T mutation in two siblings with persistent ocular pain after corneal axon transection: impaired slow inactivation and hyperexcitable trigeminal neurons","volume":"129","author":"Ghovanloo","year":"2023","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.bmc.2025.118180_b0255","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/hmg\/ddad152","article-title":"Erythromelalgia caused by the missense mutation p. Arg220Pro in an alternatively spliced exon of SCN9A (NaV1.7)","volume":"33","author":"Deuis","year":"2024","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1016\/j.bmc.2025.118180_b0260","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/jns.12590","article-title":"Genetic, electrophysiological, and pathological studies on patients with SCN9A-related pain disorders","volume":"28","author":"Yuan","year":"2023","journal-title":"J Peripheral Nervous System: JPNS"},{"key":"10.1016\/j.bmc.2025.118180_b0265","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.neuron.2021.03.012","article-title":"A central mechanism of analgesia in mice and humans lacking the sodium channel Na(V)1.7","volume":"109","author":"MacDonald","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.bmc.2025.118180_b0270","unstructured":"Ahuja S, Mukund S, Deng L, et al. Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist. 2015;350(6267): aac5464."},{"key":"10.1016\/j.bmc.2025.118180_b0275","doi-asserted-by":"crossref","first-page":"14791","DOI":"10.1038\/s41598-020-71135-2","article-title":"Discovery of a selective, state-independent inhibitor of NaV1.7 by modification of guanidinium toxins","volume":"10","author":"Pajouhesh","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118180_b0280","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0896-6273(00)81133-2","article-title":"From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels","volume":"26","author":"Catterall","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.bmc.2025.118180_b0285","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/s41589-020-0644-4","article-title":"The conformational cycle of a prototypical voltage-gated sodium channel","volume":"16","author":"Catterall","year":"2020","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2025.118180_b0290","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1021\/ar5002878","article-title":"Ion selectivity strategies of sodium channel selectivity filters","volume":"47","author":"Dudev","year":"2014","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.bmc.2025.118180_b0295","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neuron.2005.06.012","article-title":"Ion permeation through a voltage- sensitive gating pore in brain sodium channels having voltage sensor mutations","volume":"47","author":"Sokolov","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.bmc.2025.118180_b0300","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1038\/s41467-023-40514-4","article-title":"A mechanistic reinterpretation of fast inactivation in voltage-gated Na+ channels","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"issue":"33","key":"10.1016\/j.bmc.2025.118180_b0305","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2209164119","article-title":"Unwinding and spiral sliding of S4 and domain rotation of VSD during the electromechanical coupling in Na(v)1.7","volume":"119","author":"Huang","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2025.118180_b0310","doi-asserted-by":"crossref","first-page":"17930","DOI":"10.1038\/s41598-020-74591-y","article-title":"Computational pipeline to probe NaV1.7 gain-of-function variants in neuropathic painful syndromes","volume":"10","author":"Toffano","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118180_b0315","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cell.2018.12.018","article-title":"Structural Basis of Nav1.7 Inhibition by a Gating-Modifier Spider Toxin","volume":"176","author":"Xu","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2025.118180_b0320","doi-asserted-by":"crossref","first-page":"9241","DOI":"10.1038\/srep09241","article-title":"Synergetic Action of Domain II and IV Underlies Persistent Current Generation in Nav1.3 as revealed by a tarantula toxin","volume":"5","author":"Tang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118180_b0325","doi-asserted-by":"crossref","DOI":"10.1126\/science.aav8573","article-title":"Structural basis of \u03b1-scorpion toxin action on Nav channels","volume":"363","author":"Clairfeuille","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.bmc.2025.118180_b0330","doi-asserted-by":"crossref","DOI":"10.3390\/md20010047","article-title":"An Updated Review of Tetrodotoxin and Its Peculiarities","volume":"20","author":"Katikou","year":"2022","journal-title":"Mar Drugs"},{"key":"10.1016\/j.bmc.2025.118180_b0335","doi-asserted-by":"crossref","DOI":"10.3390\/toxins13080517","article-title":"From Poison to Promise: The Evolution of Tetrodotoxin and Its Potential as a Therapeutic","volume":"13","author":"Bucciarelli","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.bmc.2025.118180_b0340","doi-asserted-by":"crossref","first-page":"18338","DOI":"10.1002\/anie.201901564","article-title":"Tetrodotoxin: History, Biology, and Synthesis","volume":"58","author":"Makarova","year":"2019","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2025.118180_b0345","doi-asserted-by":"crossref","DOI":"10.3390\/md21050316","article-title":"Efficacy and Security of Tetrodotoxin in the Treatment of Cancer-Related Pain: Systematic Review and Meta-Analysis","volume":"21","author":"Huerta","year":"2023","journal-title":"Mar Drugs"},{"key":"10.1016\/j.bmc.2025.118180_b0350","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.pbb.2009.02.013","article-title":"Tetrodotoxin reduces cue-induced drug craving and anxiety in abstinent heroin addicts","volume":"92","author":"Shi","year":"2009","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.bmc.2025.118180_b0355","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1440-1681.2011.05539.x","article-title":"Tetrodotoxin alleviates acute heroin withdrawal syndrome: a multicentre, randomized, double-blind, placebo-controlled study","volume":"38","author":"Song","year":"2011","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.bmc.2025.118180_b0360","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3390\/toxins13070483","article-title":"Tetrodotoxin, a Potential Drug for Neuropathic and Cancer Pain Relief?","volume":"13","author":"Gonz\u00e1lez-Cano","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.bmc.2025.118180_b0365","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1002\/anie.201308235","article-title":"Saxitoxin","volume":"53","author":"Thottumkara","year":"2014","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2025.118180_b0370","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1039\/D0NP00051E","article-title":"The chemistry and biology of guanidine secondary metabolites","volume":"38","author":"Berlinck","year":"2021","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.bmc.2025.118180_b0375","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1021\/acs.accounts.0c00810","article-title":"Chemoenzymatic Total Synthesis of Natural Products","volume":"54","author":"Chakrabarty","year":"2021","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.bmc.2025.118180_b0380","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/rapm-00115550-200001000-00010","article-title":"The local anesthetic properties and toxicity of saxitonin homologues for rat sciatic nerve block in vivo","volume":"25","author":"Kohane","year":"2000","journal-title":"Reg Anesth Pain Med"},{"key":"10.1016\/j.bmc.2025.118180_b0385","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/j.pain.0000000000002112","article-title":"Antinociceptive properties of an isoform-selective inhibitor of Nav1.7 derived from saxitoxin in mouse models of pain","volume":"162","author":"Beckley","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.bmc.2025.118180_b0390","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1111\/bph.13985","article-title":"Differential binding of tetrodotoxin and its derivatives to voltage-sensitive sodium channel subtypes (Na(v) 1.1 to Na(v) 1.7)","volume":"174","author":"Tsukamoto","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2025.118180_b0395","article-title":"Synthetic Approaches to Zetekitoxin AB, a Potent Voltage-Gated Sodium Channel Inhibitor","volume":"18","author":"Adachi","year":"2020","journal-title":"Marine Drugs"},{"issue":"44","key":"10.1016\/j.bmc.2025.118180_b0400","doi-asserted-by":"crossref","first-page":"18102","DOI":"10.1073\/pnas.1206952109","article-title":"Marked difference in saxitoxin and tetrodotoxin affinity for the human nociceptive voltage-gated sodium channel (Nav1.7) [corrected]","volume":"109","author":"Walker","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2025.118180_b0405","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1126\/science.aaw2493","article-title":"Structures of human Nav1.7 channel in complex with auxiliary subunits and animal toxins","volume":"363","author":"Shen","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.bmc.2025.118180_b0410","doi-asserted-by":"crossref","first-page":"800","DOI":"10.4103\/1673-5374.382233","article-title":"The pathogenic mechanism of TAR DNA-binding protein 43 (TDP-43) in amyotrophic lateral sclerosis","volume":"19","author":"Wang","year":"2024","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.bmc.2025.118180_b0415","article-title":"Advances in Understanding and Treating Amyotrophic Lateral Sclerosis (ALS): A Comprehensive Review","volume":"15","author":"Gupta","year":"2023","journal-title":"Cureus."},{"key":"10.1016\/j.bmc.2025.118180_b0420","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-3-319-55769-4_11","article-title":"Glutamate Transport System as a Novel Therapeutic Target in Chronic Pain: Molecular Mechanisms and Pharmacology","volume":"16","author":"Gegelashvili","year":"2017","journal-title":"Adv Neurobiol"},{"key":"10.1016\/j.bmc.2025.118180_b0425","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1038\/s41467-023-38942-3","article-title":"Structural mapping of Nav1.7 antagonists","volume":"14","author":"Wu","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2025.118180_b0430","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/14737175.2016.1210512","article-title":"Therapeutic approach to pain in neurodegenerative diseases: current evidence and perspectives","volume":"17","author":"de Tommaso","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.bmc.2025.118180_b0435","doi-asserted-by":"crossref","unstructured":"Foley P, Parker RA, de Angelis F, et al. Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial. Multiple sclerosis and related disorders. 2022;63:103925.","DOI":"10.1016\/j.msard.2022.103925"},{"key":"10.1016\/j.bmc.2025.118180_b0440","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1021\/acsmedchemlett.3c00224","article-title":"Development of Riluzole Analogs with Improved Use-Dependent Inhibition of Skeletal Muscle Sodium Channels","volume":"14","author":"Farinato","year":"2023","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118180_b0445","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1476-5381.2011.01415.x","article-title":"On the relationship between block of the cardiac Na+ channel and drug-induced prolongation of the QRS complex","volume":"164","author":"Harmer","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2025.118180_b0450","doi-asserted-by":"crossref","unstructured":"Huang J, Fan X, Jin X, et al. Dual-pocket inhibition of Nav channels by the antiepileptic drug lamotrigine. 2023;120(41): e2309773120.","DOI":"10.1073\/pnas.2309773120"},{"key":"10.1016\/j.bmc.2025.118180_b0455","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/epi4.12644","article-title":"Anti-seizure efficacy and retention rate of carbamazepine is highly variable in randomized controlled trials: A meta-analysis","volume":"7","author":"Olaciregui-Dague","year":"2022","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.bmc.2025.118180_b0460","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.seizure.2020.10.018","article-title":"Current role of carbamazepine and oxcarbazepine in the management of epilepsy","volume":"83","author":"Beydoun","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.bmc.2025.118180_b0465","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1684\/epd.2014.0704","article-title":"The clinical pharmacology of traditional antiepileptic drugs","volume":"16","author":"Vajda","year":"2014","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.bmc.2025.118180_b0470","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/epd2.20069","article-title":"Pharmacological aspects of antiseizure medications: From basic mechanisms to clinical considerations of drug interactions and use of therapeutic drug monitoring","volume":"25","author":"Johannessen Landmark","year":"2023","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.bmc.2025.118180_b0475","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","article-title":"The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond","volume":"35","author":"L\u00f6scher","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bmc.2025.118180_b0480","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/bph.12534","article-title":"Properties of human brain sodium channel \u03b1-subunits expressed in HEK293 cells and their modulation by carbamazepine, phenytoin and lamotrigine","volume":"171","author":"Qiao","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2025.118180_b0485","first-page":"31","article-title":"Possible Clinical and Pharmacogenetic Predictors of the Efficacy and Safety of Carbamazepine in Post-COVID-19 Depression","volume":"34","author":"Vaiman","year":"2022","journal-title":"Psychiatr Danub"},{"key":"10.1016\/j.bmc.2025.118180_b0490","doi-asserted-by":"crossref","DOI":"10.3390\/medicina57050433","article-title":"Efficacy of Carbamazepine and Its Derivatives in the Treatment of Bipolar Disorder","volume":"57","author":"Grunze","year":"2021","journal-title":"Medicina"},{"key":"10.1016\/j.bmc.2025.118180_b0495","doi-asserted-by":"crossref","first-page":"s199","DOI":"10.4103\/0028-3886.315996","article-title":"Medical Management of Trigeminal Neuralgia","volume":"69","author":"Khadilkar","year":"2021","journal-title":"Neurol India"},{"key":"10.1016\/j.bmc.2025.118180_b0500","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/practneurol-2020-002782","article-title":"Trigeminal neuralgia: a practical guide","volume":"21","author":"Lambru","year":"2021","journal-title":"Pract Neurol"},{"key":"10.1016\/j.bmc.2025.118180_b0505","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12920-022-01302-z","article-title":"A novel SCN9A gene variant identified in a Chinese girl with paroxysmal extreme pain disorder (PEPD): a rare case report","volume":"15","author":"Hua","year":"2022","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.bmc.2025.118180_b0510","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202403636","article-title":"Photoswitchable Carbamazepine Analogs for Non-Invasive Neuroinhibition In Vivo","volume":"63","author":"Camerin","year":"2024","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2025.118180_b0515","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12871-023-02348-x","article-title":"Epidural nalbuphine versus dexmedetomidine as adjuvants to bupivacaine in lower limb orthopedic surgeries for postoperative analgesia: a randomized controlled trial","volume":"23","author":"Farmawy","year":"2023","journal-title":"BMC Anesthesiol"},{"key":"10.1016\/j.bmc.2025.118180_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2023.07.047","article-title":"Laparoscopic administration of bupivacaine at the uterosacral ligaments during benign laparoscopic and robotic hysterectomy: a randomized controlled trial","volume":"229","author":"Frost","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bmc.2025.118180_b0525","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s40265-021-01551-9","article-title":"Bupivacaine\/Meloxicam Prolonged Release: A Review in Postoperative Pain","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2025.118180_b0530","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/1568026013395335","article-title":"From cocaine to ropivacaine: the history of local anesthetic drugs","volume":"1","author":"Ruetsch","year":"2001","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2025.118180_b0535","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/ALN.0000000000003630","article-title":"Clinical Effectiveness of Liposomal Bupivacaine Administered by Infiltration or Peripheral Nerve Block to Treat Postoperative Pain","volume":"134","author":"Ilfeld","year":"2021","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bmc.2025.118180_b0540","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bpa.2019.07.012","article-title":"Liposomal bupivacaine and novel local anesthetic formulations","volume":"33","author":"Prabhakar","year":"2019","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"10.1016\/j.bmc.2025.118180_b0545","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1113\/jphysiol.2004.081646","article-title":"Compound-specific Na+ channel pore conformational changes induced by local anaesthetics","volume":"564","author":"Fukuda","year":"2005","journal-title":"J Physiol"},{"key":"10.1016\/j.bmc.2025.118180_b0550","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/mol.116.106401","article-title":"Lacosamide Inhibition of Nav1.7 Voltage-Gated Sodium Channels: Slow Binding to Fast-Inactivated States","volume":"91","author":"Jo","year":"2017","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bmc.2025.118180_b0555","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1021\/acschemneuro.3c00757","article-title":"Molecular Pharmacology of Selective Na(V)1.6 and Dual Na(V)1.6\/Na(V)1.2 Channel Inhibitors that Suppress Excitatory Neuronal Activity Ex Vivo","volume":"15","author":"Goodchild","year":"2024","journal-title":"ACS Chem Nerosci"},{"key":"10.1016\/j.bmc.2025.118180_b0560","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/molpharm.120.000079","article-title":"Characterization of Vixotrigine, a Broad-Spectrum Voltage-Gated Sodium Channel Blocker","volume":"99","author":"Hinckley","year":"2021","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bmc.2025.118180_b0565","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2009.12.027","article-title":"Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites","volume":"630","author":"Leffler","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmc.2025.118180_b0570","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1213\/ANE.0000000000000646","article-title":"A Comparative Analysis of Bupivacaine and Ropivacaine Effects on Human Cardiac SCN5A Channels","volume":"120","author":"Schwoerer","year":"2015","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bmc.2025.118180_b0575","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1586\/14737175.5.6.729","article-title":"Lamotrigine for neuropathic pain","volume":"5","author":"Eisenberg","year":"2005","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.bmc.2025.118180_b0580","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/head.14367","article-title":"Lacosamide for refractory trigeminal neuralgia and other facial pain-Case report","volume":"62","author":"Masrour","year":"2022","journal-title":"Headache"},{"key":"10.1016\/j.bmc.2025.118180_b0585","article-title":"Lamotrigine add-on therapy for drug-resistant focal epilepsy","volume":"12","author":"Panebianco","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bmc.2025.118180_b0590","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1515\/jbcpp-2016-0013","article-title":"Comparative pre-emptive analgesic efficacy study of novel antiepileptic agents gabapentin, lamotrigine and topiramate in patients undergoing major surgeries at a tertiary care hospital: a randomized double blind clinical trial","volume":"28","author":"Bhosale","year":"2017","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"10.1016\/j.bmc.2025.118180_b0595","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1007\/s12325-020-01388-w","article-title":"Prevalence and Management Challenges in Central Post-Stroke Neuropathic Pain: A Systematic Review and Meta-analysis","volume":"37","author":"Liampas","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.bmc.2025.118180_b0600","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/08869634.2020.1804233","article-title":"Lacosamide in trigeminal neuralgia: report of a case refractory to first- and second-generation anticonvulsants","volume":"41","author":"Adamo","year":"2023","journal-title":"Cranio"},{"issue":"1\u20132","key":"10.1016\/j.bmc.2025.118180_b0605","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2006.04.009","article-title":"Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy","volume":"539","author":"Beyreuther","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmc.2025.118180_b0610","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/head.14505","article-title":"Oral lacosamide for the treatment of refractory trigeminal neuralgia: A retrospective analysis of 86 cases","volume":"63","author":"Mu\u00f1oz-Vendrell","year":"2023","journal-title":"Headache"},{"key":"10.1016\/j.bmc.2025.118180_b0615","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1016\/j.bmc.2008.05.003","article-title":"Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain","volume":"16","author":"Drizin","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118180_b0620","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1124\/mol.113.091173","article-title":"Block of human cardiac sodium channels by lacosamide: evidence for slow drug binding along the activation pathway","volume":"85","author":"Wang","year":"2014","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bmc.2025.118180_b0625","article-title":"The role of cannabinoids in pain modulation in companion animals","volume":"9","author":"Miranda-Cort\u00e9s","year":"2022","journal-title":"Front Vet Sci"},{"key":"10.1016\/j.bmc.2025.118180_b0630","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2020.00561","article-title":"A Balanced Approach for Cannabidiol Use in Chronic Pain","volume":"11","author":"Argueta","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2025.118180_b0635","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2023.1224452","article-title":"Therapeutic efficacy and pharmacokinetics of liposomal-cannabidiol injection: a pilot clinical study in dogs with naturally-occurring osteoarthritis","volume":"10","author":"Shilo-Benjamini","year":"2023","journal-title":"Front Vet Sci"},{"key":"10.1016\/j.bmc.2025.118180_b0640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282920","article-title":"Combined non-psychoactive Cannabis components cannabidiol and \u03b2-caryophyllene reduce chronic pain via CB1 interaction in a rat spinal cord injury model","volume":"18","author":"Eeswara","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2025.118180_b0645","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-animal-081122-070236","article-title":"Scientific Validation of Cannabidiol for Management of Dog and Cat Diseases","volume":"11","author":"Corsato Alvarenga","year":"2023","journal-title":"Annu Rev Anim Biosci"},{"key":"10.1016\/j.bmc.2025.118180_b0650","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/j.japh.2020.06.009","article-title":"CBD for the treatment of pain: What is the evidence?","volume":"60","author":"Svensson","year":"2020","journal-title":"J Am Pharmacists Assoc: JAPhA"},{"key":"10.1016\/j.bmc.2025.118180_b0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.107013","article-title":"IUPHAR review- Preclinical models of neuropathic pain: Evaluating multifunctional properties of natural cannabinoid receptors ligands","volume":"199","author":"Benamar","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2025.118180_b0660","doi-asserted-by":"crossref","unstructured":"Pan X, Li Z, Zhou Q, et al. Structure of the human voltage-gated sodium channel Nav1.4 in complex with beta1. 2018;362(6412): eaau2486.","DOI":"10.1126\/science.aau2486"},{"key":"10.1016\/j.bmc.2025.118180_b0665","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1038\/s41467-023-39307-6","article-title":"Cannabidiol inhibits Na(v) channels through two distinct binding sites","volume":"14","author":"Huang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2025.118180_b0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101971","article-title":"Efficacy and safety of vixotrigine in idiopathic or diabetes-associated painful small fibre neuropathy (CONVEY): a phase 2 placebo-controlled enriched-enrolment randomised withdrawal study","volume":"59","author":"Faber","year":"2023","journal-title":"EClinicalMedicine."},{"key":"10.1016\/j.bmc.2025.118180_b0675","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/bc.bc_46_19","article-title":"Role of vinpocetine in ischemic stroke and poststroke outcomes: A critical review","volume":"6","author":"Al-Kuraishy","year":"2020","journal-title":"Brain Circul"},{"key":"10.1016\/j.bmc.2025.118180_b0680","doi-asserted-by":"crossref","unstructured":"Sharif S, Guirguis A, Fergus S, et al. The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review. 2021;11(3): 355.","DOI":"10.3390\/brainsci11030355"},{"key":"10.1016\/j.bmc.2025.118180_b0685","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6481812","article-title":"Repurposing of the Nootropic Drug Vinpocetine as an Analgesic and Anti-Inflammatory Agent: Evidence in a Mouse Model of Superoxide Anion-Triggered Inflammation","volume":"2019","author":"Lourenco-Gonzalez","year":"2019","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.bmc.2025.118180_b0690","first-page":"680","article-title":"Vinpocetine and piracetam exert antinociceptive effect in visceral pain model in mice","volume":"58","author":"Abdel Salam","year":"2006","journal-title":"Pharmacol Rep: PR"},{"key":"10.1016\/j.bmc.2025.118180_b0695","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3389\/fphar.2020.00753","article-title":"Leishmanicidal Potential of Hardwickiic Acid Isolated From Croton sylvaticus","volume":"11","author":"Crentsil","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2025.118180_b0700","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1055\/s-2006-962818","article-title":"Isolation and Insecticidal Activity of (-)-Hardwickiic Acid from Croton aromaticus","volume":"53","author":"Bandara","year":"1987","journal-title":"Planta Med"},{"key":"10.1016\/j.bmc.2025.118180_b0705","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1021\/acschemneuro.8b00617","article-title":"(\u2212)-Hardwickiic Acid and Hautriwaic Acid Induce Antinociception via Blockade of Tetrodotoxin-Sensitive Voltage-Dependent Sodium Channels","volume":"10","author":"Cai","year":"2019","journal-title":"ACS Chem Nerosci"},{"key":"10.1016\/j.bmc.2025.118180_b0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2021.113883","article-title":"Antinociceptive and anti-inflammatory activities of Copaifera pubiflora Benth oleoresin and its major metabolite ent-hardwickiic acid","volume":"271","author":"S\u00edmaro","year":"2021","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.bmc.2025.118180_b0715","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1124\/jpet.103.051086","article-title":"Vinpocetine Is a Potent Blocker of Rat NaV1.8 Tetrodotoxin-Resistant Sodium Channels","volume":"306","author":"Zhou","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmc.2025.118180_b0720","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1016\/j.bmcl.2011.04.088","article-title":"Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain","volume":"21","author":"Chowdhury","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118180_b0725","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41594-022-00860-1","article-title":"Structural basis for NaV1.7 inhibition by pore blockers","volume":"29","author":"Zhang","year":"2022","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.bmc.2025.118180_b0730","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.84151","article-title":"Cryo-EM reveals an unprecedented binding site for Na(V)1.7 inhibitors enabling rational design of potent hybrid inhibitors","volume":"12","author":"Kschonsak","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.bmc.2025.118180_b0735","doi-asserted-by":"crossref","first-page":"13063","DOI":"10.1021\/jacs.7b06506","article-title":"The Role of Disulfide Bond Replacements in Analogues of the Tarantula Toxin ProTx-II and Their Effects on Inhibition of the Voltage-Gated Sodium Ion Channel Nav1.7","volume":"139","author":"Wright","year":"2017","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2025.118180_b0740","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00109-017-1599-0","article-title":"The NA(v)1.7 blocker protoxin II reduces burn injury-induced spinal nociceptive processing","volume":"96","author":"Torres-P\u00e9rez","year":"2018","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.bmc.2025.118180_b0745","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1021\/jm500687u","article-title":"Studies examining the relationship between the chemical structure of protoxin II and its activity on voltage gated sodium channels","volume":"57","author":"Park","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118180_b0750","doi-asserted-by":"crossref","DOI":"10.1085\/jgp.202313368","article-title":"Elucidating molecular mechanisms of protoxin-II state-specific binding to the human NaV1.7 channel","volume":"156","author":"Ngo","year":"2024","journal-title":"J Gen Physiol"},{"key":"10.1016\/j.bmc.2025.118180_b0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110735","article-title":"High-resolution structures of human Nav1.7 reveal gating modulation through \u03b1-\u03c0 helical transition of S6IV","volume":"39","author":"Huang","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.bmc.2025.118180_b0760","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.peptides.2013.03.011","article-title":"Potency optimization of Huwentoxin-IV on hNav1.7: a neurotoxin TTX-S sodium-channel antagonist from the venom of the Chinese bird-eating spider Selenocosmia huwena","volume":"44","author":"Revell","year":"2013","journal-title":"Peptides"},{"key":"10.1016\/j.bmc.2025.118180_b0765","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.chembiol.2019.10.011","article-title":"Development of Photocrosslinking Probes Based on Huwentoxin-IV to Map the Site of Interaction on Nav1.7","volume":"27","author":"Tzakoniati","year":"2020","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmc.2025.118180_b0770","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/09298665113206660119","article-title":"Analgesic effects of Huwentoxin-IV on animal models of inflammatory and neuropathic pain","volume":"21","author":"Liu","year":"2014","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.bmc.2025.118180_b0775","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.bbamem.2017.01.020","article-title":"Spider peptide toxin HwTx-IV engineered to bind to lipid membranes has an increased inhibitory potency at human voltage-gated sodium channel hNaV1.7","volume":"1859","author":"Agwa","year":"2017","journal-title":"Biochimica et Biophysica Acta (BBA) \u2013 Biomembranes"},{"key":"10.1016\/j.bmc.2025.118180_b0780","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.molcel.2020.10.039","article-title":"Structural Basis for High-Affinity Trapping of the NaV1.7 Channel in Its Resting State by Tarantula Toxin","volume":"81","author":"Wisedchaisri","year":"2021","journal-title":"Mol Cell"},{"key":"10.1016\/j.bmc.2025.118180_b0785","doi-asserted-by":"crossref","first-page":"14187","DOI":"10.1073\/pnas.1922903117","article-title":"Employing NaChBac for cryo-EM analysis of toxin action on voltage-gated Na(+) channels in nanodisc","volume":"117","author":"Gao","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2025.118180_b0790","doi-asserted-by":"crossref","first-page":"22707","DOI":"10.1074\/jbc.M113.461392","article-title":"Analysis of the structural and molecular basis of voltage-sensitive sodium channel inhibition by the spider toxin huwentoxin-IV (\u03bc-TRTX-Hh2a)","volume":"288","author":"Minassian","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2025.118180_b0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e15423","article-title":"Reduced pain sensitivity of episodic pain syndrome model mice carrying a Nav1.9 mutation by ANP-230, a novel sodium channel blocker","volume":"9","author":"Okuda","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.bmc.2025.118180_b0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150126","article-title":"Unique electrophysiological property of a novel Nav1.7, Nav1.8, and Nav1.9 sodium channel blocker, ANP-230","volume":"721","author":"Kamei","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmc.2025.118180_b0805","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1006\/exnr.2002.8029","article-title":"Inhibition of neuronal Na+ channels by the novel antiepileptic compound DCUKA: identification of the diphenylureido moiety as an inactivation modifier","volume":"178","author":"Wang","year":"2002","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bmc.2025.118180_b0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2016.05.006","article-title":"A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic pain","volume":"784","author":"Tabakoff","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmc.2025.118180_b0815","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejphar.2005.01.030","article-title":"The anti-nociceptive agent ralfinamide inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive Na+ currents in dorsal root ganglion neurons","volume":"510","author":"Stummann","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmc.2025.118180_b0820","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.pain.2008.04.020","article-title":"Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat","volume":"139","author":"Zhang","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.bmc.2025.118180_b0825","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41401-021-00682-9","article-title":"Inhibition of Nav1.7 channel by a novel blocker QLS-81 for alleviation of neuropathic pain","volume":"42","author":"Niu","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.bmc.2025.118180_b0830","first-page":"935","article-title":"Newron Pharmaceuticals","volume":"7","author":"Ralfinamide","year":"2004","journal-title":"Drugs: Investig Drugs J"},{"key":"10.1016\/j.bmc.2025.118180_b0835","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00408-022-00589-0","article-title":"Tackling the Neuropathic Cough of Idiopathic Pulmonary Fibrosis (IPF): More Needs to be Done","volume":"200","author":"Chung","year":"2022","journal-title":"Lung"},{"key":"10.1016\/j.bmc.2025.118180_b0840","doi-asserted-by":"crossref","unstructured":"Noor-Mohammadi E, LIGON C, Meerveld BG-V, et al. A Novel Charged Sodium-Channel Blocker, Ntx-1175, Is Effective In Reducing Acute Visceral Hypersensitivity In Vivo. 2023;385(S3): 453.","DOI":"10.1124\/jpet.122.216180"},{"key":"10.1016\/j.bmc.2025.118180_b0845","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.760567","article-title":"Zinc Finger Proteins in Neuro-Related Diseases Progression","volume":"15","author":"Bu","year":"2021","journal-title":"Front Neurosci"},{"key":"10.1016\/j.bmc.2025.118180_b0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2019.110955","article-title":"Structural zinc binding sites shaped for greater works: Structure-function relations in classical zinc finger, hook and clasp domains","volume":"204","author":"Padjasek","year":"2020","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.bmc.2025.118180_b0855","doi-asserted-by":"crossref","first-page":"339","DOI":"10.36849\/JDD.6857","article-title":"Double-Blind, Placebo-Controlled Study of Onabotulinumtoxin A for the Treatment of Hailey-Hailey Disease","volume":"22","author":"Saal","year":"2023","journal-title":"J Drugs Dermatol: JDD"},{"key":"10.1016\/j.bmc.2025.118180_b0860","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bbrc.2020.09.103","article-title":"Recombinant PaurTx-3, a spider toxin, inhibits sodium channels and decreases membrane excitability in DRG neurons","volume":"533","author":"Chen","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmc.2025.118180_b0865","unstructured":"A 2-stage, Phase 2a Study to Evaluate the Efficacy, Safety, and Tolerability of OLP-1002 Subcutaneous Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in a Hip and\/or Knee Joint. In: Novotech Pty L, ed.; 2021."},{"key":"10.1016\/j.bmc.2025.118180_b0870","unstructured":"Therapeutics C. Pipeline; https:\/\/channeltherapeutics.com\/pipeline\/. Accessed 02-12 2025."},{"key":"10.1016\/j.bmc.2025.118180_b0875","unstructured":"A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain. 2025."},{"key":"10.1016\/j.bmc.2025.118180_b0880","unstructured":"Vstpro. Halneuron\u00ae (Tetrodotoxin for Injection) received FDA fast-track designation. 2024."}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962500121X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962500121X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:36:58Z","timestamp":1775097418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096808962500121X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":176,"alternative-id":["S096808962500121X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118180","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brief analysis of Nav1.7 inhibitors: Mechanism of action and new research trends","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"118180"}}